This environment was marked by a reduced presence of effector cells, particularly CD8+ cytotoxic T cells and activated NK cells, thereby reinforcing the involvement of Siglec-7 in tumor growth in breast cancer patients, essentially through immunosuppressive cell subsets. The gene discussed is CD8A; the disease is breast cancer.